<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00235898</url>
  </required_header>
  <id_info>
    <org_study_id>03-CoFactor</org_study_id>
    <nct_id>NCT00235898</nct_id>
  </id_info>
  <brief_title>Clinical Trial in Patients With Metastatic Colorectal Cancer</brief_title>
  <official_title>A Multi-Center, Open Label, Parallel Group, Randomised, Phase IIB Clinical Trial to Evaluate the Safety and Efficacy of CoFactor and 5-FU Versus Leucovorin and 5-FU in Subjects With Metastatic Colorectal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mast Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mast Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this trial is to compare efficacy and safety of CoFactor and 5-fluorouracil
      (5-FU) versus leucovorin and 5-FU in treatment of metastatic colorectal cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Colon Cancer</condition>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CoFactor, 5-FU</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Leucovorin, 5-FU</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CoFactor</intervention_name>
    <arm_group_label>1</arm_group_label>
    <other_name>ANX-510</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>5-Fluorouracil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have surgically incurable, confirmed metastatic colon or rectal adenocarcinoma.

          -  Be male or non-pregnant, non-lactating female subjects â‰¥ 18 years of age.

          -  If female, and of childbearing potential, agree to use adequate contraception (as
             deemed by the investigator) throughout their participation in this study and for 30
             days after discontinuation of study medication.

          -  If, female of childbearing potential, have a negative pregnancy test prior to the
             start of the study.

          -  Have a life expectancy of at least 6 months.

          -  Have radiologically or clinically measurable disease for response assessment. Presence
             of ascites or pleural effusion(s) are not acceptable as single sites of response
             assessment, but may be present if dimensional or other discrete measurable disease is
             present for evaluation.

          -  Have an ECOG Performance Level of 0-2 (or Karnofsky of 100-70). A lower ECOG or
             Karnofsky is acceptable only if clearly due to non-oncologic conditions (e.g., prior
             paraplegia from polio).

          -  Have had no prior chemotherapy for established, metastatic disease. (Subjects may have
             received adjuvant chemotherapy with fluoropyrimidine therapy).

          -  Have at least 6 months elapsed since prior adjuvant 5-FU or CPT-11 therapy, or
             Mitomycin C or nitrosourea therapy.

          -  Have had at least an 8 week interval since any prior radiation therapy or 4 weeks
             since any major surgery.

          -  Have recovered from any toxicities resulting from prior therapies (except for
             alopecia).

          -  Adequate renal, bone marrow, liver function defined as serum creatinine less than 1.5
             times the upper limit of normal, serum bilirubin less than 2 times the upper limit of
             normal, ANC greater than 1.5 x 109/L, Platelet count greater than 90 x 109/L, SGOT
             (AST) and SGPT (ALT) less than 3 times the upper limit of normal.

        Exclusion Criteria:

          -  Failure by the subject or the subject's legal representative to sign the Informed
             Consent.

          -  An inability to obtain Informed Consent because of psychiatric or complex medical
             problems.

          -  Have concurrent infection including diagnoses of FUO or evidence of possible central
             line sepsis (subjects must be afebrile at the start of therapy).

          -  Have unstable oncologic emergency syndromes: superior vena cava (SVC) syndrome, rising
             bilirubin needing stent placement, spinal cord compression, progressive brain
             metastases, active bleeding, hypercalcemia, etc.

          -  Have unstable medical conditions such as acute coronary syndrome, cardio-vascular
             accident within the previous 12 months (such as transient ischemic attacks,
             accelerated hypertension), etc.

          -  Have cerebellar neurologic syndromes such as Parkinson's disease, multiple sclerosis,
             and amyotonia.

          -  Have a known intolerance to fluoropyrimidine (5-FU, Capecitabine, Floxuridine, UFT)
             therapy (dihydropyrimidine dehydrogenase deficiency).

          -  Patients with vomiting, diarrhea, or nausea of grade greater than 1.

          -  Received any investigational drug or agent/procedure, i.e. participation in another
             trial within 4 weeks before beginning treatment with study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Cassidy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beatson Oncology Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Global Hospital</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500 004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medical Oncology, Nizam's Institute of Medical Sciences</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>560 082</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kasturba Medical College</name>
      <address>
        <city>Mangalore</city>
        <state>Attavar</state>
        <zip>575001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medical Oncology, Deenanath Mangeshkar Hospital and Research Centre</name>
      <address>
        <city>Pune</city>
        <state>Erandawane</state>
        <zip>411004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medical Oncology, Kidwai Memorial Institute of Oncology</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Christian Medical College</name>
      <address>
        <city>Vellore</city>
        <state>Tamil Nadu</state>
        <zip>632004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manipal Hospital</name>
      <address>
        <city>Bangalore</city>
        <zip>560017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SMS Medical College Hospital</name>
      <address>
        <city>Jaipur</city>
        <zip>302004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medical Oncology, Dayanad Medical College and Hospital</name>
      <address>
        <city>Ludhiana</city>
        <zip>141001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medical Oncology, Jaslok Hospital and Research Centre</name>
      <address>
        <city>Mumbai</city>
        <zip>400 026</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorectal Cancer Clinic, Centrum Cancer Clinic Onkologii-Instytut im M. Skladowskiej-Curie</name>
      <address>
        <city>Roentgena</city>
        <state>Warszawa</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department and Clinic for Oncology and Radiotherapy</name>
      <address>
        <city>Gdansk</city>
        <zip>80-211</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department for Oncology and Radiotherapy, Szpital Morski im. PCK</name>
      <address>
        <city>Gdynia Redlowo</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncological Chemotherapy Clinic, Regionalny Osrodek Onkologiczny</name>
      <address>
        <city>Lodz</city>
        <zip>93-509</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncological Chemotherapy Department Centrum Onkologii Ziemi</name>
      <address>
        <city>Lublin</city>
        <zip>20-090</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Oncology Department, Wojewodski Szpital Zespolony</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology and Hepatology Department, Fundeni Clinical Institute</name>
      <address>
        <city>Bucharest</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Professor of Dr. Alexandru Trestioreanu, Institute of Oncology II</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medical Oncology and Radiotherapy II</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400015</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Department, County Hospital Sibiu</name>
      <address>
        <city>Sibiu</city>
        <zip>550245</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Serbia</name>
      <address>
        <city>Belgrade</city>
        <zip>11 000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology and Radiology Serbia</name>
      <address>
        <city>Belgrade</city>
        <zip>11 000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHC Bezanijska</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHC Kragujevac</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic Centre Nis</name>
      <address>
        <city>Nis</city>
        <zip>21104</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic for Internal Medicine, Institute for Oncology Sremska</name>
      <address>
        <city>Sremska Kamenica</city>
        <zip>21104</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Djordje Joanovic</name>
      <address>
        <city>Zrenjanin</city>
        <zip>23000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haematology/Lung/GI Cancer Services</name>
      <address>
        <city>Harlow</city>
        <state>Essex</state>
        <zip>CM20 1QX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Research, North Middlesex University Hospital</name>
      <address>
        <city>Middlesex</city>
        <state>London</state>
        <zip>N18 1QX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beatson Oncology Centre</name>
      <address>
        <city>Glasgow</city>
        <zip>G11 6NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Serbia</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Former Serbia and Montenegro</country>
  </removed_countries>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2005</study_first_submitted>
  <study_first_submitted_qc>October 10, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2005</study_first_posted>
  <last_update_submitted>August 22, 2008</last_update_submitted>
  <last_update_submitted_qc>August 22, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2008</last_update_posted>
  <responsible_party>
    <name_title>Joachim Schupp, MD</name_title>
    <organization>Adventrx Pharmaceuticals</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

